УНЕМОРИ Элейн (US),ТЕЙЧМАН Сэм Л. (US),ДШИТЦИГ Томас (US),СТЬЮАРТ Деннис Р. (US),ВАЙТХАУС Марта Джо (US)
申请号：
RU2010151470/15
公开号：
RU2010151470A
申请日:
2009.05.15
申请国别(地区):
RU
年份:
2012
代理人:
摘要：
1. A method of treating heart failure, comprising administering a pharmaceutically active relaxin to a person, said subject having a heart failure of class II or class III according to the classification of heart failure of the Association of New York Cardiologists, in an amount that is therapeutically effective to reduce the frequency or duration of decompensation. ! 2. The method according to claim 1, in which the decompensation includes requiring unscheduled medical care symptom selected from shortness of breath, swelling and fatigue. ! 3. The method according to claim 1, in which the decompensation includes one or more of the following features: increased fluid retention in the body, hypotension, hypertension, arrhythmia, decreased renal blood flow, increased levels of circulating N-terminal prohormone of the brain natriuretic peptide (BNP or NT-pro -BNP), elevated blood urea nitrogen (AMA), and elevated creatinine levels. ! 4. The method according to claim 2, in which decompensation requires the introduction of an intravenous diuretic. ! 5. The method according to claim 1, further comprising reducing the risk of death due to heart failure. ! 6. The method according to claim 1, in which the systolic blood pressure in a subject is about 85 mm Hg or more. ! 7. The method according to claim 1, in which the introduction further reduces one or more of the following features: systemic vascular resistance, wedging pressure in the capillaries of the pulmonary artery, pulmonary vascular resistance, blood urea nitrogen, creatinine and circulating N-terminal prohormone of the cerebral natriuretic peptide . ! 8. The method according to claim 1, in which the subject does not need hospitalization due to acute heart1. Способ лечения сердечной недостаточности, включающий введение фармацевтически активного релаксина человеку, причем у указанного субъекта имеется сердечная недостаточность II класса или III класса по классификации сердечной недостаточности Ассоциации кардиологов Н
